| Yuan Yuan Xie, | |
|
70 Doctors Park, Cape Girardeau, MO 63703-4928 | |
| (573) 334-6071 | |
| (573) 334-4739 |
| Full Name | Yuan Yuan Xie |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 12 Years |
| Location | 70 Doctors Park, Cape Girardeau, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083018428 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 2020005833 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southeasthealth | Cape girardeau, MO | Hospital |
| Saint Francis Medical Center | Cape girardeau, MO | Hospital |
| Lourdes Hospital | Paducah, KY | Hospital |
| Poplar Bluff Regional Medical Center | Poplar bluff, MO | Hospital |
| Memorial Hospital Of Carbondale | Carbondale, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Hospital Perry | 1153777826 | 84 |
| Boone Physician Services Llc | 6507090644 | 226 |
| Cape Radiology Group Pc | 9830093236 | 49 |
| Cape Radiology Group Pc | 9830093236 | 49 |
| Cape Radiology Group Pc | 9830093236 | 49 |
News Archive
A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.
Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: 'Method for terminating methadone maintenance through extinction of the opiate-taking responses', using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines.
Delcath Systems, Inc. announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.
California is also preparing for a boom of children who will soon qualify for dental care in the Medicaid program. In the meantime, transitions in the Kansas' Medicaid program encounter problems.
A study commissioned by three leading scientific institutions has demonstrated substantial financial and social benefits from investment in medical research.
› Verified 3 days ago
| Entity Name | Cape Radiology Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477506392 PECOS PAC ID: 9830093236 Enrollment ID: O20031126000174 |
News Archive
A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.
Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: 'Method for terminating methadone maintenance through extinction of the opiate-taking responses', using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines.
Delcath Systems, Inc. announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.
California is also preparing for a boom of children who will soon qualify for dental care in the Medicaid program. In the meantime, transitions in the Kansas' Medicaid program encounter problems.
A study commissioned by three leading scientific institutions has demonstrated substantial financial and social benefits from investment in medical research.
› Verified 3 days ago
| Entity Name | Boone Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760893259 PECOS PAC ID: 6507090644 Enrollment ID: O20131003000535 |
News Archive
A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.
Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: 'Method for terminating methadone maintenance through extinction of the opiate-taking responses', using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines.
Delcath Systems, Inc. announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.
California is also preparing for a boom of children who will soon qualify for dental care in the Medicaid program. In the meantime, transitions in the Kansas' Medicaid program encounter problems.
A study commissioned by three leading scientific institutions has demonstrated substantial financial and social benefits from investment in medical research.
› Verified 3 days ago
| Entity Name | Mercy Hospital Perry |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063117158 PECOS PAC ID: 1153777826 Enrollment ID: O20231101001515 |
News Archive
A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.
Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: 'Method for terminating methadone maintenance through extinction of the opiate-taking responses', using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines.
Delcath Systems, Inc. announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.
California is also preparing for a boom of children who will soon qualify for dental care in the Medicaid program. In the meantime, transitions in the Kansas' Medicaid program encounter problems.
A study commissioned by three leading scientific institutions has demonstrated substantial financial and social benefits from investment in medical research.
› Verified 3 days ago
| Entity Name | Mercy Hospital Perry |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1063117158 PECOS PAC ID: 1153777826 Enrollment ID: O20231106001433 |
News Archive
A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.
Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: 'Method for terminating methadone maintenance through extinction of the opiate-taking responses', using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines.
Delcath Systems, Inc. announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.
California is also preparing for a boom of children who will soon qualify for dental care in the Medicaid program. In the meantime, transitions in the Kansas' Medicaid program encounter problems.
A study commissioned by three leading scientific institutions has demonstrated substantial financial and social benefits from investment in medical research.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yuan Yuan Xie, 70 Doctors Park, Cape Girardeau, MO 63703-4928 Ph: (573) 334-6071 | Yuan Yuan Xie, 70 Doctors Park, Cape Girardeau, MO 63703-4928 Ph: (573) 334-6071 |
News Archive
A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.
Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: 'Method for terminating methadone maintenance through extinction of the opiate-taking responses', using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines.
Delcath Systems, Inc. announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.
California is also preparing for a boom of children who will soon qualify for dental care in the Medicaid program. In the meantime, transitions in the Kansas' Medicaid program encounter problems.
A study commissioned by three leading scientific institutions has demonstrated substantial financial and social benefits from investment in medical research.
› Verified 3 days ago
Karen B Willens, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-335-6671 | |
Jeffrey William Boss, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 Fax: 573-334-4739 | |
Dr. Lance C. Faler, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 | |
Dr. Justin Ray Hodge, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctor's Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 Fax: 573-334-4739 | |
Abel Assefa Belay, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 | |
Dr. George A. Pjura, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 Fax: 573-334-4739 |